ZA201906822B - Indole ahr inhibitors and uses thereof - Google Patents
Indole ahr inhibitors and uses thereofInfo
- Publication number
- ZA201906822B ZA201906822B ZA2019/06822A ZA201906822A ZA201906822B ZA 201906822 B ZA201906822 B ZA 201906822B ZA 2019/06822 A ZA2019/06822 A ZA 2019/06822A ZA 201906822 A ZA201906822 A ZA 201906822A ZA 201906822 B ZA201906822 B ZA 201906822B
- Authority
- ZA
- South Africa
- Prior art keywords
- ahr inhibitors
- indole
- inhibitors
- indole ahr
- ahr
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 title 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488476P | 2017-04-21 | 2017-04-21 | |
| US201762592542P | 2017-11-30 | 2017-11-30 | |
| US201862658454P | 2018-04-16 | 2018-04-16 | |
| PCT/US2018/028532 WO2018195397A2 (en) | 2017-04-21 | 2018-04-20 | Indole ahr inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201906822B true ZA201906822B (en) | 2024-06-26 |
Family
ID=63856153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/06822A ZA201906822B (en) | 2017-04-21 | 2019-10-16 | Indole ahr inhibitors and uses thereof |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US10570138B2 (https=) |
| EP (2) | EP4710923A2 (https=) |
| JP (2) | JP7232244B2 (https=) |
| KR (1) | KR102668371B1 (https=) |
| CN (1) | CN110831600B (https=) |
| AU (1) | AU2018256459B2 (https=) |
| CA (1) | CA3059939A1 (https=) |
| CL (1) | CL2019003015A1 (https=) |
| CO (1) | CO2019011584A2 (https=) |
| FI (1) | FI3612030T3 (https=) |
| IL (1) | IL270025B2 (https=) |
| MX (1) | MX2019012431A (https=) |
| NZ (1) | NZ758243A (https=) |
| PT (1) | PT3612030T (https=) |
| SG (1) | SG11201909710XA (https=) |
| TW (1) | TWI778050B (https=) |
| WO (1) | WO2018195397A2 (https=) |
| ZA (1) | ZA201906822B (https=) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| LT3555097T (lt) | 2016-12-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai |
| MX392743B (es) * | 2017-04-12 | 2025-03-12 | Magenta Therapeutics Inc | Antagonistas del receptor de hidrocarburo de arilo y sus usos. |
| WO2018195397A2 (en) | 2017-04-21 | 2018-10-25 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
| FR3066761B1 (fr) * | 2017-05-23 | 2020-10-30 | Centre Nat Rech Scient | Nouveaux composes inhibiteurs des canaux ioniques |
| WO2019036657A1 (en) | 2017-08-17 | 2019-02-21 | Kyn Therapeutics | AHR INHIBITORS AND USES THEREOF |
| ES2946632T7 (es) | 2018-02-06 | 2025-03-04 | Ideaya Biosciences Inc | Moduladores de AhR |
| WO2019156989A1 (en) * | 2018-02-06 | 2019-08-15 | Ideaya Biosciences, Inc. | COMPOUNDS AND METHODS FOR THE MODULATION OF AhR |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| JP7448527B2 (ja) * | 2018-09-07 | 2024-03-12 | 大塚製薬株式会社 | ヘテロ環式化合物 |
| US20220144839A1 (en) * | 2018-10-16 | 2022-05-12 | Ikena Oncology, Inc. | Indole ahr inhibitors and uses thereof |
| WO2020081840A1 (en) * | 2018-10-17 | 2020-04-23 | Magenta Therapeutics Inc. | Methods of treating cancer with aryl hydrocarbon receptor antagonists |
| EA202191507A1 (ru) * | 2018-11-30 | 2021-08-20 | Селулэрити Инк. | Ароматические соединения для применения для активации кроветворных стволовых клеток и клеток-предшественников |
| CN113454207A (zh) * | 2018-11-30 | 2021-09-28 | 细胞结构公司 | 用新型芳香族化合物扩增自然杀伤细胞和ilc3细胞 |
| CN109813913B (zh) * | 2019-01-31 | 2021-11-09 | 中国医学科学院肿瘤医院 | 芳烃受体(AhR)在预测免疫治疗效果中的应用 |
| KR20210131316A (ko) | 2019-02-27 | 2021-11-02 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Sumo-활성화 효소 저해제 및 관문 저해제의 투여 |
| EP4710922A2 (en) * | 2019-07-30 | 2026-03-18 | Oregon State University | Aryl hydrocarbon receptor activators |
| EP4061484A1 (en) * | 2019-11-22 | 2022-09-28 | Senda Biosciences, Inc. | Pyridopyrimidinone derivatives as ahr antagonists |
| PT4065582T (pt) * | 2019-11-26 | 2025-05-22 | Ikena Oncology Inc | Derivados polimórficos do carbazol e utilizações dos mesmos |
| US20230041743A1 (en) * | 2019-11-26 | 2023-02-09 | Hoffmann-La Roche Inc. | 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease |
| BR112022010143A2 (pt) | 2019-11-26 | 2022-08-09 | Ikena Oncology Inc | Inibidores de ahr e usos respectivos |
| TW202146416A (zh) | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| KR20220125323A (ko) | 2020-01-10 | 2022-09-14 | 이케나 온콜로지, 인코포레이티드 | Ahr 억제제 및 이의 용도 |
| US20230279000A1 (en) | 2020-02-26 | 2023-09-07 | Jaguahr Therapeutics Pte Ltd | Pyridopyrimidine derivatives useful in modulation of ahr signalling |
| CN115397818A (zh) * | 2020-03-27 | 2022-11-25 | 东亚St株式会社 | 氨基嘧啶衍生物及其作为芳烃受体调节剂的应用 |
| WO2021236717A1 (en) | 2020-05-20 | 2021-11-25 | Senda Biosciences, Inc. | Fused imidazole derivatives as ahr antagonists |
| US11857551B1 (en) | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
| WO2022029063A1 (en) * | 2020-08-04 | 2022-02-10 | Bayer Aktiengesellschaft | Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines |
| WO2022078356A1 (zh) * | 2020-10-15 | 2022-04-21 | 山东轩竹医药科技有限公司 | 杂芳环类AhR抑制剂 |
| IL302346A (en) | 2020-10-28 | 2023-06-01 | Ikena Oncology Inc | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
| CN114644627B (zh) * | 2020-12-18 | 2024-06-11 | 山东轩竹医药科技有限公司 | AhR抑制剂及其用途 |
| CN112656789A (zh) * | 2020-12-31 | 2021-04-16 | 中国科学院生态环境研究中心 | Ficz在抑制肿瘤细胞迁移中的应用 |
| CN114805361B (zh) * | 2021-01-17 | 2024-02-20 | 上海凌达生物医药有限公司 | 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途 |
| BR112023018286A2 (pt) | 2021-03-11 | 2023-10-31 | Janssen Pharmaceutica Nv | Lorpucitinib para uso no tratamento de distúrbios mediados por jak |
| WO2023020512A1 (zh) * | 2021-08-16 | 2023-02-23 | 成都奥睿药业有限公司 | 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途 |
| WO2023033741A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| KR20240054994A (ko) * | 2021-09-02 | 2024-04-26 | 재규어 테라퓨틱스 피티이 리미티드 | AhR 시그널링의 조절에 유용한 화합물 |
| WO2023033742A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| CN115093400B (zh) * | 2021-09-18 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR抑制剂及其用途和制备方法 |
| WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN115925684B (zh) * | 2021-12-03 | 2025-02-28 | 徐诺药业(南京)有限公司 | 一种嘧啶类衍生物及其制备方法和应用 |
| JP2025502240A (ja) | 2022-01-11 | 2025-01-24 | ドイッチェス・クレープスフォルシュングスツェントルム | がんの治療のための二環式トリアジン誘導体 |
| AU2023249795A1 (en) | 2022-04-08 | 2024-10-17 | Shy Therapeutics, Llc | Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| CN117624168A (zh) * | 2022-08-19 | 2024-03-01 | 德明药泰生物技术（深圳）有限公司 | 稠环杂环类化合物及其制备方法和应用 |
| CN115850329A (zh) * | 2022-09-16 | 2023-03-28 | 东莞市均成高新材料有限公司 | 环三联芳膦、它们的制备方法及用途 |
| WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| CN115804776A (zh) * | 2022-12-16 | 2023-03-17 | 国纳之星(上海)纳米科技发展有限公司 | 一种芳香烃受体抑制剂和5-氟尿嘧啶合用在治疗抑制肿瘤药物中的应用 |
| CN116482278B (zh) * | 2023-05-06 | 2024-02-09 | 广州清瑞生物科技有限责任公司 | 一种用于检测阿昔洛韦的对照品的制备方法 |
| US20250084087A1 (en) * | 2023-08-18 | 2025-03-13 | Incyte Corporation | Bicyclic heterocycles as mrgprx2 antagonists |
| EP4512427A1 (en) | 2023-08-25 | 2025-02-26 | Mablink Bioscience | Antibody-drug conjugates based on molecular glue degraders and uses thereof |
| EP4512806A1 (en) | 2023-08-25 | 2025-02-26 | Mablink Bioscience | Molecular glue degraders and uses thereof |
| CN117229284B (zh) * | 2023-11-10 | 2024-02-06 | 上海泽德曼医药科技有限公司 | 三环稠杂环类化合物、其制备方法及其在医药上的应用 |
| WO2025114771A1 (en) | 2023-11-29 | 2025-06-05 | Latvian Institute Of Organic Synthesis | A new class of aryl hydrocarbon receptor antagonists and their optimisation |
| WO2025254418A1 (ko) * | 2024-06-03 | 2025-12-11 | 동아에스티 주식회사 | 아미노피리미딘 유도체의 결정다형 및 이의 제조방법 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721356A (en) | 1989-09-15 | 1998-02-24 | Gensia, Inc. | Orally active adenosine kinase inhibitors |
| HU228962B1 (en) * | 1996-07-24 | 2013-07-29 | Bristol Myers Squibb Pharma Co | Azolo triazines, pharmaceutical compositions containing them and use of the compounds |
| US5962473A (en) | 1996-08-16 | 1999-10-05 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| EP1343506A1 (de) | 2000-12-19 | 2003-09-17 | MERCK PATENT GmbH | Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate |
| US20040235877A1 (en) | 2001-09-14 | 2004-11-25 | Natsuki Ishizuka | Novel use of tricyclic compound |
| CA2497444C (en) * | 2002-09-04 | 2010-11-30 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| ATE378336T1 (de) * | 2002-09-19 | 2007-11-15 | Schering Corp | Imidazopyridine als hemmstoffe cyclin abhängiger kinasen |
| EP1610774A4 (en) | 2003-04-09 | 2008-07-16 | Exelixis Inc | TIE-2 MODULATORS AND METHODS OF USE |
| PE20051128A1 (es) | 2004-02-25 | 2006-01-16 | Schering Corp | Pirazolotriazinas como inhibidores de quinasa |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| KR20070118068A (ko) * | 2004-11-23 | 2007-12-13 | 레디 유에스 테라퓨틱스 인코포레이티드 | 신규의 이원 헤테로고리 화합물, 그 제조방법 및 이들을포함하는 조성물 |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| CA2634198C (en) | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| ES2444574T3 (es) | 2006-09-19 | 2014-02-25 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa |
| BRPI0718029A2 (pt) * | 2006-11-06 | 2013-11-26 | Supergen Inc | Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| CA2708361C (en) * | 2007-12-14 | 2016-06-07 | F. Hoffmann-La Roche Ag | Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives |
| US20110176972A1 (en) | 2008-05-29 | 2011-07-21 | Saint-Gobain Centre De Recherches et D'Etudes Eur | Cellular structure containing aluminium titanate |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| CN102762208A (zh) | 2009-12-04 | 2012-10-31 | 赛林药物股份有限公司 | 作为ck2抑制剂的吡唑嘧啶和相关杂环 |
| PH12012500881A1 (en) | 2009-12-10 | 2017-07-26 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| CA2789076C (en) | 2010-03-05 | 2017-11-21 | F. Hoffmann-La Roche Ag | Antibodies against human colony stimulating factor-1 receptor and uses thereof |
| MX378336B (es) | 2010-05-04 | 2025-03-10 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| US8957077B2 (en) * | 2010-09-30 | 2015-02-17 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine PDE 10 inhibitors |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| MX363696B (es) * | 2011-04-21 | 2019-03-28 | Origenis Gmbh | Pirazolo[4,3-d]pirimidinas utiles como inhibidores de cinasas. |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CA2858069C (en) * | 2011-12-08 | 2020-02-11 | Novartis Ag | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| AR090650A1 (es) * | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo |
| EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2014060112A1 (en) | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
| WO2014138485A1 (en) * | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
| JP2018525345A (ja) | 2015-07-01 | 2018-09-06 | ノースウェスタン ユニバーシティ | 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用 |
| TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
| MX392743B (es) | 2017-04-12 | 2025-03-12 | Magenta Therapeutics Inc | Antagonistas del receptor de hidrocarburo de arilo y sus usos. |
| WO2018195397A2 (en) | 2017-04-21 | 2018-10-25 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
| US20220144839A1 (en) | 2018-10-16 | 2022-05-12 | Ikena Oncology, Inc. | Indole ahr inhibitors and uses thereof |
| PT4065582T (pt) | 2019-11-26 | 2025-05-22 | Ikena Oncology Inc | Derivados polimórficos do carbazol e utilizações dos mesmos |
| BR112022010143A2 (pt) | 2019-11-26 | 2022-08-09 | Ikena Oncology Inc | Inibidores de ahr e usos respectivos |
| KR20220125323A (ko) | 2020-01-10 | 2022-09-14 | 이케나 온콜로지, 인코포레이티드 | Ahr 억제제 및 이의 용도 |
| IL302346A (en) | 2020-10-28 | 2023-06-01 | Ikena Oncology Inc | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
-
2018
- 2018-04-20 WO PCT/US2018/028532 patent/WO2018195397A2/en not_active Ceased
- 2018-04-20 FI FIEP18787414.4T patent/FI3612030T3/fi active
- 2018-04-20 TW TW107113564A patent/TWI778050B/zh active
- 2018-04-20 AU AU2018256459A patent/AU2018256459B2/en active Active
- 2018-04-20 CA CA3059939A patent/CA3059939A1/en active Pending
- 2018-04-20 KR KR1020197034489A patent/KR102668371B1/ko active Active
- 2018-04-20 MX MX2019012431A patent/MX2019012431A/es unknown
- 2018-04-20 SG SG11201909710X patent/SG11201909710XA/en unknown
- 2018-04-20 PT PT187874144T patent/PT3612030T/pt unknown
- 2018-04-20 CN CN201880038301.XA patent/CN110831600B/zh active Active
- 2018-04-20 EP EP25224138.5A patent/EP4710923A2/en active Pending
- 2018-04-20 JP JP2020507495A patent/JP7232244B2/ja active Active
- 2018-04-20 NZ NZ758243A patent/NZ758243A/en unknown
- 2018-04-20 US US15/958,586 patent/US10570138B2/en active Active
- 2018-04-20 EP EP18787414.4A patent/EP3612030B1/en active Active
-
2019
- 2019-10-16 ZA ZA2019/06822A patent/ZA201906822B/en unknown
- 2019-10-17 IL IL270025A patent/IL270025B2/en unknown
- 2019-10-18 CO CONC2019/0011584A patent/CO2019011584A2/es unknown
- 2019-10-21 CL CL2019003015A patent/CL2019003015A1/es unknown
- 2019-10-30 US US16/668,070 patent/US10689388B1/en active Active
-
2020
- 2020-04-08 US US16/843,606 patent/US11358969B2/en active Active
-
2022
- 2022-05-06 US US17/662,246 patent/US12077542B2/en active Active
- 2022-06-06 JP JP2022091740A patent/JP2022116319A/ja not_active Withdrawn
-
2024
- 2024-07-12 US US18/771,297 patent/US20250122205A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201906822B (en) | Indole ahr inhibitors and uses thereof | |
| MX2021004245A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
| MX2020001793A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
| MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| WO2020243415A3 (en) | Tead inhibitors and uses thereof | |
| PH12021553018A1 (en) | New egfr inhibitors | |
| MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| MX2020006812A (es) | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. | |
| PH12022551522A1 (en) | Smarca degraders and uses thereof | |
| MY205416A (en) | Tyk2 inhibitors and uses thereof | |
| MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
| PH12018500408A1 (en) | Bicyclic compounds as atx inhibitors | |
| MX2018009773A (es) | Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4). | |
| MX2018005292A (es) | Inhibidores de acc y usos de los mismos. | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2018001890A (es) | Compuestos biciclicos como inhibidores de autotaxina (atx). | |
| MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
| MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| PH12015502041B1 (en) | Heteroaryl compounds and uses thereof | |
| MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
| PH12018500409A1 (en) | New bicyclic compounds as dual atx/ca inhibitors | |
| MX2018006288A (es) | Inhibidores de acc tipo ester y usos de los mismos. | |
| EA201691916A1 (ru) | Биарильные ингибиторы киназы |